|作者：||Yan Jie-Yu, Zhang Jin-Long, Wang Mao-Qiang, Yuan Kai, Bai Yan-Hua, Wang Yan, Xin Hai-Nan, Wang Zhi-Jun, Liu Feng-Yong, Duan Feng, Fu Jin-Xin|
1Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
2School of Medicine, Nankai University, Tianjin, China.
|刊名：||Asia-Pacific journal of clinical oncology, 2018, Vol.14 (4), pp.300-309|
|关键词：||Combined treatment; Hepatocellular carcinoma (HCC); Interventional oncology; Radiofrequency ablation (RFA); Transcatheter arterial chemoembolization (TACE);|
|原始语种摘要：||AIMS(#br)To evaluate technical feasibility and treatment results of combined transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in single-session for solitary hepatocellular carcinoma (HCC) larger than 7 cm in diameter.(#br)METHODS(#br)Institutional review board approved this retrospective study. Written informed consent was obtained from all patients. Between June 2007 and July 2013, 87 patients (75 men, 12 women; mean age, 55.5 years ± 15.0) with solitary HCC with a mean maximum diameter of 9.5 cm ± 2.4 (range, 7.1-13.5 cm) not feasible for surgical resection underwent combined TACE and RFA in a single-session. Immediately following TACE, RFA was performed under fluoroscopy and CB-CT guidance. The primary endpoint was overall survival (OS). The secondary... endpoints were technical safety and local tumor progression (LTP) rates. OS and time to progression (TTP) were analyzed with the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify prognostic factors affecting OS and TTP.(#br)RESULTS(#br)Technical success of combined TACE and RFA in a single-session was achieved in all patients (100%). On 1-month follow-up MRI, complete response (CR) was observed in 76 of 87 patients (87.4 %), partial response (PR) in 8 and stable disease (SD) in 3 patients. The median follow-up period was 49.5 months (interquartile range, 30.0-70.0 months). The median OS was 39 months (range, 15-86 months). The cumulative OS rates at 1, 3 and 5 years were 100%, 65.5% and 47.5%, respectively. The estimated 1, 3 and 5 year LTP rates were 0 %, 29.9% and 55.2 %, respectively. Univariate and multivariate analyses showed a tumor larger than 10.0 cm (P < 0.05) and presence of portal vein branch invasion (P < 0.05) led to the worst prognosis. No major complications were noted.(#br)CONCLUSIONS(#br)Combined use of TACE and RFA in single-session is a safe and effective option in the treatment of patients with solitary large HCC (> 7 cm) not amenable to surgery.|